FDA Accepts Genentech's Fenebrutinib Filing for Multiple Sclerosis

Key Facts

1The U.S. FDA accepted the filing for fenebrutinib, making it the first BTK inhibitor to be reviewed for both relapsing and primary progressive multiple sclerosis.

The U.S. FDA accepted the filing for fenebrutinib, making it the first BTK inhibitor to be reviewed for both relapsing and primary progressive multiple sclerosis. Business Wire reported that the investigational drug aims to address two distinct forms of the disease, marking a significant regulatory milestone for Genentech.

The filing is supported by clinical data demonstrating the drug's potential in treating both relapsing and primary progressive MS. While the acceptance of the filing is a key step in the regulatory process for this new drug class, final approval from the FDA remains pending.